Animal Studies

动物研究

基本信息

项目摘要

Core C is the animal core. The core will provide technical service to preclinical projects 1, and 2 establishing subcutaneous and systemic tumor models, assessing uptake of radiolabeled agents, determining therapeutic efficacy of radiolabeled antibody conjugates and haptens, and identifying toxicity associated with single and multimodal treatment protocols. It will also collect blood for toxicity assessments and tissue for the histological analysis .by Core E. It will use 2 F/T technicians to manage 2160-2560 mice per year in its AAALAC-accredited facility. Specifically it will be responsible for the following tasks: (a) developing new tumor models in untreated and immunosuppressed mice, (b) injecting cultured tumor cells intravenously or subcutaneously in SCID mice or nude mice, (c) dosing animals with appropriate therapeutic agents [e.g., bispecific antibodies, radiolabeled haptens, radioantibodies, naked antibodies, and chemotherapeutics], (d) monitoring survival, body weight changes and onset of hind-leg paralysis in systemic tumor models and measuring tumor size of subcutaneous tumors by 3D caliper measurements, (e) performing biodistribution studies, (f) providing fixed samples of tumors and tissues for histology to monitor viability and to monitor expression of antigens by immunohistology and for microautoradiography studies, (g) collecting blood samples for white blood cell and platelet enumeration and for measurement of cardiac troponin in project 4, (h) entering all data (biodistribution, therapy, WBC/Plt, body weight) into Excel spreadsheets, and (i) setting up immunoscintigraphy studies.
核心C是动物核心。核心将为临床前项目1、2的建立提供技术服务

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

ROSALYN D BLUMENTHAL其他文献

ROSALYN D BLUMENTHAL的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('ROSALYN D BLUMENTHAL', 18)}}的其他基金

Chronobiological Principles to Maximize Efficacy of Alt*
最大化 Alt 功效的时间生物学原理*
  • 批准号:
    6570707
  • 财政年份:
    2003
  • 资助金额:
    $ 19.51万
  • 项目类别:
PRE-CLINICAL COMBINATION CHEMO- AND RADIOANTIBODY THERAP
临床前化疗和放射抗体联合治疗
  • 批准号:
    6725403
  • 财政年份:
    2002
  • 资助金额:
    $ 19.51万
  • 项目类别:
PRE-CLINICAL COMBINATION CHEMO/RADIOANTIBODY THERAPY
临床前联合化疗/放射抗体治疗
  • 批准号:
    6376968
  • 财政年份:
    2002
  • 资助金额:
    $ 19.51万
  • 项目类别:
PRE-CLINICAL COMBINATION CHEMO- AND RADIOANTIBODY THERAP
临床前化疗和放射抗体联合治疗
  • 批准号:
    6620132
  • 财政年份:
    2002
  • 资助金额:
    $ 19.51万
  • 项目类别:
PRE TARGETED THERAPY USING THE NOVEL TACHYKININ (NK) REC
使用新型速激肽 (NK) REC 进行预靶向治疗
  • 批准号:
    6175066
  • 财政年份:
    2000
  • 资助金额:
    $ 19.51万
  • 项目类别:
CORE--ANIMAL LABORATORY
核心--动物实验室
  • 批准号:
    6300383
  • 财政年份:
    2000
  • 资助金额:
    $ 19.51万
  • 项目类别:
EFFECT OF TARGETED LOW DOSE RADIATION TREATMENT ON TUMOR OXYGENATION
靶向低剂量放射治疗对肿瘤氧合的影响
  • 批准号:
    6353194
  • 财政年份:
    2000
  • 资助金额:
    $ 19.51万
  • 项目类别:
PRE TARGETED THERAPY USING THE NOVEL TACHYKININ (NK) REC
使用新型速激肽 (NK) REC 进行预靶向治疗
  • 批准号:
    6378018
  • 财政年份:
    2000
  • 资助金额:
    $ 19.51万
  • 项目类别:
FACTORS IN COMBINED RADIOIMMUNOTHERAPY AND CHEMOTHERAPY IN CANCER MANAGEMENT
癌症治疗中放射免疫治疗和化疗联合治疗的因素
  • 批准号:
    6300386
  • 财政年份:
    2000
  • 资助金额:
    $ 19.51万
  • 项目类别:
CORE--ANIMAL LABORATORY
核心--动物实验室
  • 批准号:
    6102693
  • 财政年份:
    1999
  • 资助金额:
    $ 19.51万
  • 项目类别:

相似海外基金

Rationally guided discovery platform for monoclonal antibodies against carbohydrate antigens using virus-like particle conjugate immunization and high throughput selection
使用病毒样颗粒缀合物免疫和高通量选择的合理引导的针对碳水化合物抗原的单克隆抗体的发现平台
  • 批准号:
    10574738
  • 财政年份:
    2023
  • 资助金额:
    $ 19.51万
  • 项目类别:
Assessing the role of liver stage antigens-specific antibodies against Plasmodium falciparum liver stage infection
评估肝期抗原特异性抗体对抗恶性疟原虫肝期感染的作用
  • 批准号:
    10392870
  • 财政年份:
    2021
  • 资助金额:
    $ 19.51万
  • 项目类别:
Generation of antibodies specific for optimal non-HRP2 malaria diagnostic antigens
生成最佳非 HRP2 疟疾诊断抗原的特异性抗体
  • 批准号:
    10092930
  • 财政年份:
    2020
  • 资助金额:
    $ 19.51万
  • 项目类别:
Generation of antibodies specific for optimal non-HRP2 malaria diagnostic antigens
生成最佳非 HRP2 疟疾诊断抗原的特异性抗体
  • 批准号:
    9896170
  • 财政年份:
    2020
  • 资助金额:
    $ 19.51万
  • 项目类别:
Interrogation of cell surface antigens on B lineage cells using structurally unique variable lymphocyte receptor antibodies of the evolutionarily distant sea lamprey
使用进化遥远的海七鳃鳗结构独特的可变淋巴细胞受体抗体询问 B 谱系细胞上的细胞表面抗原
  • 批准号:
    433456
  • 财政年份:
    2020
  • 资助金额:
    $ 19.51万
  • 项目类别:
    Operating Grants
Investigations of interactions between various natural antibodies and food-derived antigens
研究各种天然抗体与食物源性抗原之间的相互作用
  • 批准号:
    19K15765
  • 财政年份:
    2019
  • 资助金额:
    $ 19.51万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Identifying Kawasaki Disease-Specific Antibodies and Antigens
识别川崎病特异性抗体和抗原
  • 批准号:
    9932769
  • 财政年份:
    2018
  • 资助金额:
    $ 19.51万
  • 项目类别:
Novel Scoring Methods for Interactions between Antibodies and Antigens
抗体和抗原之间相互作用的新评分方法
  • 批准号:
    BB/P504713/1
  • 财政年份:
    2017
  • 资助金额:
    $ 19.51万
  • 项目类别:
    Training Grant
Novel Scoring Methods for Interactions between Antibodies and Antigens
抗体和抗原之间相互作用的新评分方法
  • 批准号:
    1932904
  • 财政年份:
    2017
  • 资助金额:
    $ 19.51万
  • 项目类别:
    Studentship
SBIR Phase II: Automated Design Methods of Antibodies Directed to Protein and Carbohydrate Antigens
SBIR II 期:针对蛋白质和碳水化合物抗原的抗体的自动化设计方法
  • 批准号:
    1632399
  • 财政年份:
    2016
  • 资助金额:
    $ 19.51万
  • 项目类别:
    Standard Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了